Correlation between serum IL 37 levels with keloid severity
Related Experiment Video
Updated: Dec 30, 2025
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Fathia M Khattab1, Mai A Samir1
1Department of Dermatology, Venereology, and Andrology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Background:
Keloids are dermal fibroproliferative disorders that characterized by over deposition of components of the extracellular matrix. Interleukin 37 (IL-37) is known by its ability to inhibit the proliferation of keloid fibroblasts by inhibiting extracellular matrix production induced by transforming growth factor β (TGF-β). Thus, Il-37 is suggested to be used as an early preventive treatment for keloids.
Aims:
This study aimed to evaluate the correlation between serum levels of IL37 level and the keloid severity.
Patients/Methods:
This is a cross-sectional analytic study involving thirty-two patients diagnosed clinically as having Keloid. An assessment of keloid severity was conducted by using Vancouver Scar Scale (VSS). Blood samples were collected from every patient to measure and assess the serum levels of IL37.
Results:
A negative correlation was found between IL37 level and the keloid severity (P = .0001; r = -.737). Also, there was a nonsignificant correlation between IL37 levels in patient with keloid and age, gender, duration of lesions, and family history.
Conclusion:
Lower level of plasma IL 37 could be an indicator of the severity of Keloids.
